CutisPharma, which focuses on products for the prescription compounding market, said Tuesday that it aims to advance several programs in its research and development portfolio — including RM-02, RM-03 and RM-06 — toward Food and Drug Administration approval by teaming up with Dr. Reddy’s.
“This partnership has significant strategic benefits for both parties,” stated Neal Muni, chief executive officer of CutisPharma. “Dr. Reddy’s Laboratories’ breadth of expertise and international infrastructure provide great synergy to CutisPharma’s own R&D and commercial organizations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards New Drug Application (NDA) filings.”
CutisPharma noted that it has aggressively invested in its R&D pipeline, recently announcing the opening of a state-of-the-art manufacturing center at its Wilmington, Mass., facility and completion of validation activities supporting the first NDA filing of its lead pipeline drug, RM-01, next year.
The company added that the partnership with Dr. Reddy’s Laboratories will allow for the acceleration of three additional drugs — RM-02, RM-03 and RM-06 — toward FDA approval.
“We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust health care ecosystem. The partnership with CutisPharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country,” commented Deepak Sapra, vice president and global head for CPS business at Dr. Reddy’s.
Added Muni, “By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the United States, as well as select international markets.”